-logo.jpg "Lykos Therapeutics"){kind=logo}
San Jose, United States
Lykos Therapeutics (formerly MAPS PBC) is a healthcare startup dedicated to transforming mental healthcare. Founded in 2014 and headquartered in the United States, the company's slogan reflects its commitment to driving change in the industry. With a mission to apply evidence-based research, Lykos Therapeutics is developing investigational psychedelics to catalyze therapeutic approaches for mental health conditions, focusing initially on addressing PTSD. As a Public Benefit Company, the organization prioritizes delivering a positive impact on people, communities, and society.
The company recently secured a $100.00M Series A investment on January 5, 2024, with a diverse group of notable investors including KittyHawk Ventures, True Ventures, Helena, Satori Capital, Vine Ventures, Steven & Alexandra Cohen Foundation, EIR Pharmaceuticals, Unlikely Collaborators, The Joe and Sandy Samberg Foundation, and Bail Capital.
Lykos Therapeutics' unique focus on mental healthcare and its commitment to social impact make it an intriguing investment prospect for venture capitalists seeking opportunities in the healthcare and biotech sectors.
